Related to Cancer Research UK to Conduct Phase I Trial with Merck KGaA’s B-Cell Lymphoma Candidate

• Merck KGaA Partners with European ScreeningPort on Multiple Sclerosis Research
  
• Evotec and Merck KGaA Sign Neurological Drug Discovery Deal
  
• Merck KGaA and Sanofi-Aventis to Evaluate Combinations of Phase I Anticancer Compounds
  
• MDxHealth to Develop Companion Diagnostic for Pfizer Cancer Candidate
  
• Apeiron Licenses Phase II/III Anticancer Ab-IL2 Fusion Protein from Merck KGaA
  
• Centella Partners with Cancer Research UK for Early Development of Newly Licensed Drug
  
• Leukemia & Lymphoma Society Inks Four Deals to Advance Research into the Clinic
  
• Merck KGaA to Use MDxHealth’s Assay in Second Clinical Glioblastoma Study
  
• Horizon Licenses X-Man Panel for Viral Diseases and Leukemias from the University of Minnesota
  
• Merck KGaA Returns All Rights to Anticancer TLR9 Agonists to Idera
  
• Merck KGaA Nabs Threshold’s Late-Stage Hypoxia-Targeting Anticancer Drug for Initial $25M
  
• Threshold Pharma Gets $20M from Merck KGaA After Phase II Success with Anticancer Agent
  
• BioInvent, CRT, Queen Mary College Establish Anticancer Antibody Discovery Pact
  
• Infinity Regains Rights to PI3K and FAAH Programs
  
• Myeloma Collaboration Unites Janssen, U.K. Institutions
  
• Cetrotide Manufacturing Rights Transferred to Merck Serono
  
• Novartis, Oxford BioMedica Ink Production Agreement for Lentiviral Gene Therapy
  
• Lilly Halts Development of Lymphoma Drug After Phase III Failure
  
• Lonza to Manufacture Micromet’s Blinatumomab BiTE Antibody
  
• CRT and University of Auckland Team Up to Develop Leukemia Treatments